Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT

Mercedes Gasior Kabat • 31 Aug 2020
EBMT 2020
General

Mercedes Gasior Kabat, MD, Hospital Universitario La Paz, Madrid, Spain, discusses prophylactic high-dose donor CD45RO+ memory T-cell infusion after allogeneic hemopoietic stem cell transplantation (allo-HSCT), focusing on safety and outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mercedes Gasior Kabat

T-cell depletion targeting CD45RA in HLA-mismatched HSCT
2:41
T-cell depletion targeting CD45RA in HLA-mismatched HSCT
Mercedes Gasior Kabat • 22 Jun 2021
Molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
4:22
Molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
Mercedes Gasior Kabat • 22 Jun 2021
Donor NK cell infusion to prevent HHV6 reactivation in pediatric patients
3:13
Donor NK cell infusion to prevent HHV6 reactivation in pediatric patients
Mercedes Gasior Kabat • 1 Sep 2020

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals